0
Editorial |

Adjuvant Therapy of Breast Cancer in the Elderly:  Does One Size Fit All?

William J. Gradishar, MD; Virginia G. Kaklamani, MD, DSc
JAMA. 2005;293(9):1118-1120. doi:10.1001/jama.293.9.1118.
Text Size: A A A
Published online

Extract

The impact of adjuvant therapy for treatment of early stage breast cancer has clearly reduced the risk of disease recurrence and breast cancer mortality. The evolution of adjuvant therapy for treatment of early stage breast cancer is a story of incrementalism, built on the solid observation made more 3 decades ago that administration of postoperative chemotherapy improves outcome for patients with breast cancer.1 Numerous large randomized clinical trials have subsequently reaffirmed that early observation.2 With the characterization of the estrogen receptor (ER) and the introduction of tamoxifen, adjuvant endocrine therapy proved to be highly effective as another, although not mutually exclusive, systemic approach for treatment of patients with tumors expressing ER. Additionally, the benefit of tamoxifen conferred to patients with tumors expressing ER is fairly similar across age groups.2 More recently, the introduction of selective aromatase inhibitors as adjuvant endocrine therapy in postmenopausal women appears to have incrementally improved outcome compared with tamoxifen alone.37

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Tables

References

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 3

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

Users' Guides to the Medical Literature
Table 9.2-2 Refuted Evidence From Studies of Physiologic or Surrogate Endpoints

The Rational Clinical Examination
Make the Diagnosis: Breast Cancer

brightcove.createExperiences();